Pulmonary arterial hypertension targeted for new treatment by Sheffield scientists

(University of Sheffield) Scientists at the University of Sheffield, working in collaboration with drug and vaccine developer Kymab Ltd, Cambridge, have identified a novel antibody that has the potential to become a new treatment for pulmonary arterial hypertension (PAH).